Femoro-popliteal Below Knee Bypass with a Cryopreserved Saphenous Vein Homograft Sheathed with Biocompound Tubing  by Grilli Cicilioni, C et al.
SHORT REPORT
Femoro-popliteal Below Knee Bypass with a Cryopreserved
Saphenous Vein Homograft Sheathed with Biocompound Tubing
C. Grilli Cicilioni, G. Pagliariccio, A. Angelini and P. AloÁ Francesco
Vascular Surgery Department, Torrette General Hospital ± University of Ancona, Ancona, Italy
Key Words: Homograft; Femoro-popliteal bypass; Biocompound graft.
EJVES Extra 4, 91±93 (2002)
doi:10.1053/ejvx 2002.0186, available online at http://www.sciencedirect.com onIntroduction
Aneurysmal degeneration of autologous saphenous
vein (ASV) used in femoro-distal revascularization is
a fairly frequent but not always predictable event and
involves a high risk of thrombosis of the bypass itself.
Treatment involves repair, removal and replacement
or endovascular treatment. If replacement is necessary
for revascularization with the distal anastomosis
below the knee, results with heterologous grafts are
disappointing. More favourable results can be
achieved with cryopreserved homologous veins
(CHV) or arterial allografts.1 However, a high rate of
early aneurysmal degeneration is described in most
published series. A method is now available for
sheathing and reinforcing CHV with a highly flexible
metal braided tubing. This prevents aneurysmal
degeneration and allows CHV to be used. This report
describes the replacement of an aneurysmally degen-
erated ASV bypass with a CHV which was reinforced
with biocompound tubing.
Case Report
A 40-year-old male with a history of heavy smoking
(40 cigarettes/day) and systemic arterial hypertension
underwent a below-knee femoropopliteal bypass with
`` in situ'' saphenous vein due to critical ischemia of the
lower limb in 1993.Please address all correspondence to: C. Grilli Cicilioni, Clinica di
Chirurgia Vascolare, Ospedale Regionale di Torrette, Via conca,
60100, Torrette, Ancona, Italy.
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of the lower limb and relief of the symptoms. Serial
follow-up using duplex ultrasound showed patency
of the bypass but with a significant, progressive
increase in the vein diameter after 24 months. Control
angiography showed a patent popliteal artery.
Surgery was planned for elective removal of the
bypass. When the patient was admitted to hospital,
he complained of pain in the lower limb. Duplex
examination revealed a thrombosis, making replace-
ment of the aneurysmal segment of the graft urgent.
For the replacement a segment of CHV with a length
of about 40 cm and a caliber of 5 mm was used.
Sheathing with the biocompound tubing was per-
formed on the bench (Fig. 1). An expandable, non-
compliant balloon catheter with a diameter of 5.5 mm
was inserted into the lumen of the vein, throughout its
length (Fig. 2). A highly flexible metal tubing was then
applied on the outside of the vein using a special
release set (Fig. 3). The balloon catheter was
then inflated, thus pushing outwards the tributaries
of the CHV. Then the braided tubing was adapted to
the irregular surface of the CHV by slight smoothing
out towards both ends and both were bonded together
by applying fibrin sealant (Tissucol, Fig. 4).
After polymerization of the fibrin sealant, the
balloon catheter was deflated and removed.
The ready-to-use biocompound prosthesis retains the
flexibility of the vein and at the same time it does not
obstruct penetration of the needle when suturing the
anastomosis.
After removal of the aneurysmally degenerated
bypass, a new below-knee femoropopliteal bypass was
constructed. When the patient was discharged, theicense.
Fig. 1. The cryopreserved homologus saphenous vein, the biocom-
pound mesh and the inflating balloon.
Fig. 2. The cryopreserved homologus saphenous vein inside the
inflating balloon.
Fig. 3. Placing the biocompound mesh over the vein surface.
Fig. 4. The fibrin glue seals the vein together with the mesh.
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toms. Duplex follow up at 2 years confirmed patency
of the bypass without aneurysm formation.
Discussion
The problem facing the vascular surgeon in the event
of failure of a bypass for peripheral revascularization
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the patient has a fairly long life expectancy. Treatment
options include the use of another segment of auto-
logous vein or a cryopreserved arterial or venous
segment2 or the use of synthetic grafts. None of these
alternatives is particularly satisfactory.
There are many important problems relating to the
use of CHV. The available literature regarding use of
CHV in surgery for peripheral arterial reconstruction
shows that there is a marked tendency for aneurysmal
dilation, up to 58% after 3 years.3 The primary and
secondary patency rate of CHV bypasses rises up to
53% after 5 years.4,5 On the other hand secondary
patency rate of 36% after one year are quoted.6
In this context, the biocompound type of prosthesis,
used in ectatic or unmistakably varicose autologous
saphenous vein,7 represents an alternative. In heart
surgery, the biocompound graft has already been
used with satisfactory results for a number of years.
The results of long term patency appear to be similar
to those observed for the native saphenous vein
(68.7% for native vein compared with 68.3% for the
biocompound graft8).
The application of this method to surgery for distal
revascularization of the lower limbs has so far only
been described sporadically.9 The technique used by
us was similar to that used for cardiac procedures. The
biocompound hybrid prosthesis technique was found
to be safe and simple. The technical result was good,
and so was the short-term clinical result. The associa-
tion of CHV with biocompound tubing may lead to
better long-term patency as well as reducing the dila-
tion problems that are frequent when CHV is used
alone. Furthermore, experimental studies showed
that external support of the vein wall reduces medial
and intimal proliferation, thus reducing the possibility
of the appearance of neointimal hyperplasia which
represents one of the most frequent causes of failure
of a venous bypass.10
In this particular young patient with a limited
amount of autologous vein available for otheruses (aorto-coronaric bypass or femoro-popliteal
below-knee bypass), we considered it advisable to
bond the biocompound tubing with a cryopreserved
homologous saphenous vein.
This technique is still in the initial stages and
requires evaluation with regard to time as well as
numbers; but it may be a practical alternative for
complex peripheral revascularization in the future.
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